Capital investment to expand analytical capabilities and accelerate research and development
First written in FY2017. 21 of 26 entries say "Advanced", first in FY2018-Q1. Latest entry: FY2026.
0 other companies' latest entry also says "Advanced".
- FY2026AdvancedAnnual report
「During the consolidated fiscal year, the company made capital investments to expand analytical capacity, accelerate research and development, and improve the efficiency of core operations. These investments included intangible assets as well as property, plant and equipment, bringing total capital expenditures for the consolidated fiscal year to ¥90.690 million.」
The company recorded ¥90.690 million in total capital expenditures and continued investing in analytical capacity, research and development, core operational efficiency, labor-saving robots, measuring equipment and core systems. - 2026-08-07AdvancedEarnings
「Fixed assets at the end of the current consolidated fiscal year totaled ¥512,402 thousand, an increase of ¥2,603 thousand from the end of the previous consolidated fiscal year. This was due to increases of ¥49,406 thousand in tools, furniture and fixtures associated with the introduction of labor-saving robots and measurement equipment, ¥35,476 thousand in buildings and structures due to the renewal of heating and cooling equipment, and ¥21,096 thousand in software in progress associated with the introduction of a core system.」
Capital investment in labor-saving equipment, measurement equipment, heating and cooling equipment, and a core system was reflected in the results. - FY2026-H1AdvancedAnnual report
「Net cash used in investing activities was ¥50.381 million. This reflected ¥42.599 million used to acquire property, plant and equipment such as tools, fixtures and equipment and ¥7.781 million used to acquire intangible assets.」
During the interim consolidated accounting period, the company acquired ¥42.599 million of property, plant and equipment and ¥7.781 million of intangible assets, expanding its facilities and systems base. - FY2025-H1AdvancedAnnual report
「Net cash used in investing activities was ¥163.244 million. This mainly reflected ¥113.393 million used to acquire property, plant and equipment such as tools, fixtures and equipment and ¥49.980 million used to acquire investment securities.」
The company spent ¥113.393 million to acquire property, plant and equipment, and tools, fixtures and equipment increased by ¥108.858 million, among other changes, advancing the expansion of the facilities base. - FY2024AdvancedAnnual report
「Total capital expenditures for the consolidated fiscal year were ¥146.222 million. Capital expenditures by segment were as follows.」
Of the ¥146.222 million in total capital expenditures, the Advanced Research and Development Support Business invested ¥139.370 million in the addition of mass spectrometers and other items, while company-wide investments of ¥6.852 million were made for information security enhancements and other measures. - FY2024-Q2AdvancedAnnual report
「Net cash used in investing activities was ¥26.497 million. This reflected ¥0.910 million used to acquire intangible assets such as software and ¥25.587 million used to acquire property, plant and equipment for renovation work, the purchase of lease assets and other purposes.」
The company acquired ¥0.910 million of software and other items and ¥25.587 million of property, plant and equipment, advancing the expansion of its facilities and systems base. - FY2024-Q1AdvancedAnnual report
「As a result, revenue was ¥221.257 million, down 13.5% year on year. In addition to lower revenue, higher cost of sales associated with the introduction of cutting-edge equipment and increased sales of partner services affected segment profit after allocation of corporate expenses, which was ¥3.900 million, down 89.9%.」
The introduction of advanced equipment was carried out and identified as a factor contributing to higher cost of sales. - FY2023AdvancedAnnual report
「Total capital expenditures for the consolidated fiscal year were ¥102.566 million. Capital expenditures by segment were as follows.」
Of the ¥102.566 million in total capital expenditures, the Advanced Research and Development Support Business invested ¥98.699 million in the addition of mass spectrometers and other items. For the following fiscal year, the company planned to invest ¥102.405 million in analytical equipment and other items and ¥8.580 million in servers and other equipment. - FY2023-Q3AdvancedAnnual report
「This was mainly due to an increase of ¥93.849 million in tools, fixtures and equipment as a result of capital expenditures.」
Capital expenditures increased tools, fixtures and equipment by ¥93.849 million, demonstrating the expansion of the facilities base in specific monetary terms. - FY2023-Q2AdvancedAnnual report
「Net cash used in investing activities was ¥20.837 million. This reflected ¥11.970 million used to acquire intangible assets and ¥8.867 million used to acquire property, plant and equipment.」
The company acquired ¥11.970 million of intangible assets and ¥8.867 million of property, plant and equipment, demonstrating the expansion of its facilities and systems base through specific investment amounts. - FY2022AdvancedAnnual report
「Total capital expenditures for the consolidated fiscal year were ¥182.287 million. Capital expenditures by segment were as follows. (1) Advanced Research and Development Support Business: The main capital expenditures during the consolidated fiscal year totaled ¥173.615 million, including the addition of mass spectrometers, to ensure stable operation and improve the efficiency of analysis.」
Total capital expenditures were ¥182.287 million, of which the Advanced Research and Development Support Business invested ¥173.615 million in the addition of mass spectrometers and other items. - FY2022-Q3AdvancedAnnual report
「This was mainly due to an increase of ¥110.484 million in tools, fixtures and equipment as a result of capital expenditures.」
Capital expenditures increased tools, fixtures and equipment by ¥110.484 million, demonstrating the expansion of the facilities base in specific monetary terms. - FY2022-Q2AdvancedAnnual report
「Net cash used in investing activities was ¥134.870 million. This mainly reflected ¥126.825 million used to acquire property, plant and equipment.」
During the six months ended the second quarter, the company acquired ¥126.825 million of property, plant and equipment, while tools, fixtures and equipment also increased by ¥107.755 million. The expansion of the facilities base was demonstrated by specific investment amounts. - FY2021AdvancedAnnual report
「Total capital expenditures for the consolidated fiscal year were ¥74.293 million. Capital expenditures by segment were as follows.」
Of the ¥74.293 million in total capital expenditures, the metabolomics business invested ¥71.405 million in the replacement of mass spectrometers and other items to ensure stable operation and improve the efficiency of analysis. - FY2021-Q3AdvancedAnnual report
「This was mainly due to increases of ¥44.874 million in lease assets, ¥20.517 million in tools, fixtures and equipment, and ¥34.679 million in accumulated depreciation of property, plant and equipment as a result of capital expenditures.」
Capital expenditures increased lease assets by ¥44.874 million and tools, fixtures and equipment by ¥20.517 million, advancing the expansion of the facilities base. - FY2021-Q2AdvancedAnnual report
「Net cash used in investing activities was ¥24.700 million. This mainly reflected ¥20.603 million used to acquire property, plant and equipment.」
During the six months ended the second quarter, the company acquired ¥20.603 million of property, plant and equipment and ¥0.800 million of intangible assets, among other items, expanding its facilities. - FY2020AdvancedAnnual report
「Total capital expenditures for the consolidated fiscal year were ¥35.343 million. Capital expenditures by segment were as follows.」
The company made ¥35.343 million of capital expenditures, including ¥21.381 million for the replacement of mass spectrometers, ¥9.149 million for analytical instruments for testing, and ¥4.812 million for information security enhancements and other measures. It also disclosed plans to invest ¥82.868 million in analytical equipment, freezers and other items in the following fiscal year. - FY2020-Q3RestatedAnnual report
「We also worked on business development for new pipelines and biomarker-related businesses and on strengthening research facilities.」
The company continues to strengthen its research facilities. The current text does not specify the amount of capital expenditures or the equipment introduced during the quarter. - FY2020-Q2RestatedAnnual report
「We also worked on business development for new pipelines and biomarker-related businesses and on strengthening research facilities.」
The company continues to strengthen its research facilities. The current text provides only limited details on the amount of capital expenditures and the equipment introduced during the quarter. - FY2020-Q1RestatedAnnual report
「We also worked on business development for new pipelines and biomarker-related businesses and on strengthening research facilities.」
The company continues to strengthen its research facilities. The current text does not specify the amount of capital expenditures or the equipment introduced during the quarter. - FY2019AdvancedAnnual report
「Total capital expenditures for the consolidated fiscal year were ¥155.368 million. In the metabolomics business, the company invested ¥142.833 million, including in the replacement of mass spectrometers, to ensure stable operation and improve the efficiency of analysis.」
The company replaced mass spectrometers and made other investments to expand analytical capacity and ensure stable operation, demonstrating tangible progress in capital expenditures. - FY2019-Q3AdvancedAnnual report
「Net cash used in investing activities was ¥47.791 million. This mainly reflected ¥137.738 million used to acquire property, plant and equipment and ¥100 million received from the redemption of securities.」
The company acquired ¥137.738 million of property, plant and equipment and ¥7.612 million of intangible assets, continuing to strengthen its facilities. - FY2019-Q1AdvancedAnnual report
「Net cash provided by investing activities was ¥8.120 million, compared with ¥28.422 million used in the same period of the previous year. This mainly reflected ¥81.936 million used to acquire property, plant and equipment and ¥100 million received from the redemption of securities.」
During the six months ended the second quarter, the company acquired property, plant and equipment for ¥81.936 million and continued to strengthen its facilities supporting analytical capacity and new services. - FY2018-Q4RestatedAnnual report
「The operating loss was ¥129.601 million, compared with an operating loss of ¥130.023 million in the same period of the previous year, due in part to efforts to strengthen the business platform for further growth of the Metabolome Analysis Business.」
The company continues to strengthen its foundation for further growth in the metabolomics analysis business. - FY2018-Q1AdvancedAnnual report
「In this business segment, the Group continued to conduct active promotional activities, as in the previous fiscal year, worked to expand orders for large projects in the chemical, pharmaceutical and other fields, and strengthened its organisational structure and equipment to develop new services.」
The company strengthened its organizational structure and facilities to develop new services. Capital expenditures included ¥24.229 million spent on the acquisition of property, plant and equipment during the six months ended the second quarter. - FY2017First statedAnnual report
「The company is making capital investments to expand analytical capacity, accelerate research and development, and improve the efficiency of core operations.」
The company invested ¥40.997 million in capital expenditures during the consolidated fiscal year, including the replacement of its capillary electrophoresis system and the introduction of analytical instruments and equipment for research and development.